Yue Dong, Zheng Miao
Department of Urology, Affiliated Hospital of Jining Medical University, Jining, Shandong, China.
Department of Operating Room, Affiliated Hospital of Jining Medical University, Jining, Shandong, China.
Discov Oncol. 2025 May 20;16(1):835. doi: 10.1007/s12672-025-02737-3.
Clear cell renal cell carcinoma (ccRCC) represents the most lethal form of kidney cancer, with a significant number of patients experiencing tumor progression. Succinylation modification is a novel post-translational modification (PTM) that refers to modifying a protein with a succinyl group, which most frequently happens to lysine residues. Recent studies have revealed that abnormal succinylation, altered protein activity, dysfunctional roles in energy metabolism, and subsequent epigenetic modifications are linked to the onset and progression of conditions like inflammation, cancer, and other diseases. No studies have offered a comprehensive analysis of succinylation modification in ccRCC or clarified the mechanisms by which this modification operates within disease progression. In this study, we applied quantitative proteomics and succinylation modification omics to extensively examine the global proteome and succinylation modification changes in ccRCC tissues. Using high-throughput liquid chromatography-mass spectrometry, we identified 4801 lysine succinylation modification sites across 1274 proteins in ccRCC and adjacent non-cancerous tissues. Additionally, 434 succinylation sites within 328 proteins displayed significant differential modification in ccRCC (fold change (FC) > 1.5 or p < 0.05). Notably, the succinylated proteins were primarily associated with energy metabolism pathways, including fatty acid elongation, glyoxylate and dicarboxylate metabolism, the tricarboxylic acid cycle, and oxidative phosphorylation, and were predominantly located within the mitochondria. This study is the first to present a global proteomic profile and a detailed succinylation modification landscape in ccRCC. These findings introduce new potential approaches for treating ccRCC by reversing abnormal succinylation modifications.
透明细胞肾细胞癌(ccRCC)是最致命的肾癌形式,大量患者会出现肿瘤进展。琥珀酰化修饰是一种新型的翻译后修饰(PTM),指的是用琥珀酰基团修饰蛋白质,这种修饰最常发生在赖氨酸残基上。最近的研究表明,异常的琥珀酰化、蛋白质活性改变、能量代谢中的功能失调作用以及随后的表观遗传修饰与炎症、癌症和其他疾病等病症的发生和进展有关。尚无研究对ccRCC中的琥珀酰化修饰进行全面分析,也未阐明这种修饰在疾病进展中的作用机制。在本研究中,我们应用定量蛋白质组学和琥珀酰化修饰组学广泛检测ccRCC组织中的整体蛋白质组和琥珀酰化修饰变化。通过高通量液相色谱 - 质谱联用技术,我们在ccRCC和相邻的非癌组织中鉴定出1274种蛋白质上的4801个赖氨酸琥珀酰化修饰位点。此外,328种蛋白质中的434个琥珀酰化位点在ccRCC中表现出显著的差异修饰(倍数变化(FC)> 1.5或p < 0.05)。值得注意的是,琥珀酰化蛋白质主要与能量代谢途径相关,包括脂肪酸延长、乙醛酸和二羧酸代谢、三羧酸循环以及氧化磷酸化,并且主要位于线粒体中。本研究首次呈现了ccRCC中的整体蛋白质组概况和详细的琥珀酰化修饰图谱。这些发现为通过逆转异常琥珀酰化修饰来治疗ccRCC引入了新的潜在方法。